Nature Communications (Apr 2020)

Cerebrospinal fluid p-tau217 performs better than p-tau181 as a biomarker of Alzheimer’s disease

  • Shorena Janelidze,
  • Erik Stomrud,
  • Ruben Smith,
  • Sebastian Palmqvist,
  • Niklas Mattsson,
  • David C. Airey,
  • Nicholas K. Proctor,
  • Xiyun Chai,
  • Sergey Shcherbinin,
  • John R. Sims,
  • Gallen Triana-Baltzer,
  • Clara Theunis,
  • Randy Slemmon,
  • Marc Mercken,
  • Hartmuth Kolb,
  • Jeffrey L. Dage,
  • Oskar Hansson

DOI
https://doi.org/10.1038/s41467-020-15436-0
Journal volume & issue
Vol. 11, no. 1
pp. 1 – 12

Abstract

Read online

Cerebrospinal fluid (CSF) p-tau181 (tau phosphorylated at threonine 181) is an established biomarker of Alzheimer’s disease (AD) reflecting abnormal tau metabolism in the AD brain. Here the authors demonstrate that CSF p-tau217 shows better performance as an AD biomarker than p-tau181.